Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Definium Therapeutics, Inc. filings document the regulatory record of a British Columbia clinical-stage biopharmaceutical company traded on Nasdaq as DFTX. Current reports on Form 8-K disclose financial results, corporate highlights, investor-presentation materials, and clinical and commercial updates for DT120 ODT in psychiatric indications.
Definitive proxy materials cover annual general and special meeting matters, including director elections, auditor appointment, compensation governance, and shareholder voting procedures. Other filings record board composition changes, non-employee director compensation, stock option awards, indemnity arrangements, and the company’s corporate identity following its former name, Mind Medicine (MindMed) Inc.
Definium Therapeutics, Inc. granted its Chief Commercial Officer, Matthew T. Wiley, 115,000 common shares in the form of restricted stock units (RSUs). The grant was reported as an acquisition at a price of $0.00 per share, held directly by the officer.
Each RSU represents a contingent right to receive one common share of Definium Therapeutics. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, as long as Wiley continues providing service to the company on each vesting date.
Definium Therapeutics, Inc. granted its Chief Financial Officer, Brandi Roberts, an award of 150,000 restricted stock units (RSUs). Each RSU represents the right to receive one common share.
The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, as long as Roberts continues providing service on each vesting date. The award was reported as a direct, no-cost acquisition, with 150,000 common shares beneficially owned following the transaction.
Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan reported an equity award of 125,000 common shares in the form of restricted stock units on February 3, 2026. The award was granted at a price of $0.00 per share as part of his compensation.
Each RSU represents a right to receive one common share, vesting in 16 equal quarterly installments beginning June 1, 2026, so long as he continues providing service on each vesting date. Following this grant, he beneficially owns 407,576 common shares directly.
Definium Therapeutics, Inc. Chief Medical Officer Dan Karlin reported an award of 150,000 common shares of the company on February 3, 2026. These are structured as restricted stock units, granted at a price of $0.00 per share, increasing his direct holdings to 575,025 shares.
The RSUs vest in 16 equal quarterly installments starting on June 1, 2026. Each RSU converts into one common share if he continues providing service to Definium Therapeutics on each vesting date, tying the value of this grant to his ongoing tenure.
Definium Therapeutics, Inc. reported that Chief Executive Officer and director Robert Barrow received an award of 320,000 restricted stock units (RSUs), each representing one common share. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026. After this grant, Barrow beneficially owns 1,098,477 common shares of Definium Therapeutics.
Definium Therapeutics director Roger Adsett received a grant of stock options on 01/29/2026. The award covers options to buy 50,000 common shares at an exercise price of $17.24 per share, all held directly.
The options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in 24 equal monthly installments, contingent on Mr. Adsett’s continued service to the company.
Definium Therapeutics director reports no holdings
Definium Therapeutics, Inc. director Roger Adsett filed an initial ownership report stating that he does not beneficially own any Definium Therapeutics securities. The filing is administrative in nature and does not describe any stock purchases, sales, or other transactions.
Definium Therapeutics, Inc. reported a change to its board of directors. On January 28, 2026, the board expanded from six to seven members and appointed Roger Adsett as a director effective January 29, 2026, with a term running until the 2026 annual general meeting, or until a successor is chosen or he departs earlier.
Adsett was not assigned to any board committees at this time. Under the company’s non-employee director compensation policy, he will receive an annual cash retainer of $40,000, paid quarterly on a pro-rata basis. He also received an option to purchase 50,000 common shares, vesting one-third on the first anniversary of the grant date and the remainder in equal monthly installments thereafter, subject to continued board service.
The option grant was issued under the company’s 2025 Equity Incentive Plan. The filing notes there are no special arrangements leading to his appointment and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.